Lucy Dewitt, MD
Neurology · Salt Lake City, UTNPI 1053401646
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Biogen accounts for 90.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $24,963 and has fallen 83.5% since, to $4,106 in 2023. Among neurology clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 71 payments — averaging $1142.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$73K
- EMD Serono, Inc.$7K
- Banner Life Sciences, LLC$900
What the payments were for
- Consulting fees$28,46035%
- Speaking & faculty fees$47,63859%
- Travel & lodging$3,5874%
- Food & beverage$1,3602%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 65 | $73,430 |
| EMD Serono, Inc. | 5 | $6,775 |
| Banner Life Sciences, LLC | 1 | $900 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$81,105 in reported general payments places this provider in the 90th percentile of 157 neurology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 25 | $125,092 |
| AmpyraDalfampridine | 13 | $51,611 |
| Dalfampridine ErDalfampridine | 26 | $7,735 |
| EliquisApixaban | 11 | $6,579 |
| Pregabalin | 28 | $3,319 |
| Baclofen | 82 | $1,543 |
| Atorvastatin Calcium | 24 | $526 |
| Levetiracetam | 12 | $484 |
| Modafinil | 14 | $473 |
| Lamotrigine | 11 | $417 |
| Tizanidine Hcl | 23 | $306 |
| Gabapentin | 25 | $283 |
| Ezetimibe | 13 | $168 |
| Sumatriptan Succinate | 16 | $164 |
| Memantine Hcl | 11 | $135 |
Paid to pharmacies, not to this prescriber.
Other neurology in Salt Lake City
- Timothy WestSalt Lake City$856K
- Stacey SteevesSalt Lake City$548K
- Amir ArainSalt Lake City$329K
- Mark BrombergSalt Lake City$265K
- April ErwinSalt Lake City$263K
- Albert SmithSalt Lake City$122K
- John FoleySalt Lake City$99K
- Kevin BrennanSalt Lake City$81K
- Nicholas JohnsonSalt Lake City$80K
- Viktoria KaplanSalt Lake City$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.